Dali Pharmaceuticalco.,Ltd

Shanghai Stock Exchange 603963.SS

Dali Pharmaceuticalco.,Ltd Revenue for the year ending December 31, 2023: USD 12.29 M

Dali Pharmaceuticalco.,Ltd Revenue is USD 12.29 M for the year ending December 31, 2023, a -35.91% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Dali Pharmaceuticalco.,Ltd Revenue for the year ending December 31, 2022 was USD 19.18 M, a -28.94% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue for the year ending December 31, 2021 was USD 26.99 M, a -17.52% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue for the year ending December 31, 2020 was USD 32.72 M, a -22.58% change year over year.
Dali Pharmaceuticalco.,Ltd Revenue for the year ending December 31, 2019 was USD 42.27 M, a -27.60% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 603963.SS

Dali Pharmaceuticalco.,Ltd

CEO	Mr. Jun Xiang Yang
IPO Date	Sept. 22, 2017
Location	China
Headquarters	No. 118, West Huancheng Road
Employees	272
Sector	Health Care
Industries Pharmaceuticals

Description

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.

Key trends

Past 5 years